TD Asset Management Inc Sells 20,188 Shares of Krystal Biotech, Inc. $KRYS

TD Asset Management Inc lessened its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 50.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,080 shares of the company’s stock after selling 20,188 shares during the period. TD Asset Management Inc’s holdings in Krystal Biotech were worth $2,760,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Krystal Biotech by 173.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after buying an additional 365,304 shares during the last quarter. Braidwell LP lifted its stake in shares of Krystal Biotech by 99.9% in the 1st quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after purchasing an additional 200,244 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Krystal Biotech by 3.0% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 250,514 shares of the company’s stock valued at $45,168,000 after purchasing an additional 7,344 shares during the period. Nuveen LLC acquired a new position in shares of Krystal Biotech in the 1st quarter valued at about $42,223,000. Finally, Woodline Partners LP lifted its stake in shares of Krystal Biotech by 0.4% in the 1st quarter. Woodline Partners LP now owns 222,043 shares of the company’s stock valued at $40,034,000 after purchasing an additional 941 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Trading Down 2.6%

KRYS stock opened at $190.78 on Wednesday. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $207.84. The firm has a 50 day moving average of $162.81 and a 200-day moving average of $151.55. The firm has a market capitalization of $5.52 billion, a P/E ratio of 38.78 and a beta of 0.64.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, August 4th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.08 by $0.21. Krystal Biotech had a return on equity of 15.21% and a net margin of 40.85%.The business had revenue of $96.04 million during the quarter, compared to analysts’ expectations of $95.42 million. Sell-side analysts predict that Krystal Biotech, Inc. will post 6.14 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Guggenheim set a $224.00 price target on Krystal Biotech and gave the company a “buy” rating in a research report on Friday. Chardan Capital decreased their price target on Krystal Biotech from $219.00 to $216.00 and set a “buy” rating for the company in a research report on Friday, August 22nd. Bank of America raised their price objective on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Finally, Citigroup reissued a “neutral” rating and issued a $166.00 target price (down from $176.00) on shares of Krystal Biotech in a research report on Tuesday, August 5th. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $223.00.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).